Document Detail


The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis.
MedLine Citation:
PMID:  15009104     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Several reports have indicated that the combination of calcipotriol ointment and potent or ultrapotent corticosteroids are more effective and better tolerated, as compared to the monotherapies. The aim of the present study was to find out the effect of combination of calcipotriol ointment once daily and betamethasone dipropionate ointment once daily vs. the effect of twice-daily applications of each of the two treatments as monotherapy during a four-week treatment period. Seven patients with chronic plaque psoriasis were included for treatment with the three treatment schedules. Biopsies were taken before treatment and after four weeks of treatment, and markers for epidermal proliferation (Ki-67) and epidermal differentiation (keratin-10) were studied using a quantitative image analysis, and T-cell subsets in epidermis and dermis (CD4, CD8, CD25, CD45RO, CD45RA, CD94, CD161, and CD2) were studied using immunohistochemical scoring. The most impressive clinical result was reached with the combination. Calcipotriol proved to have a major effect on the proliferation marker Ki-67 and differentiation marker keratin-10, whereas the effect on T-cell subsets was more selective with major reductions of CD45RO(+) and CD8(+) T cells. In contrast, the effect of betamethasone dipropionate on the epidermis was restricted to a normalization of differentiation with a highly significant increase of keratin-10 positive epidermal surface without a significant effect on Ki-67 positive nuclei, and the effect on T-cell subsets was restricted to a reduction of natural killer T-cell receptors designated by CD94 and CD161 in the epidermis. The combination of the two treatments did not affect the proliferation marker Ki-67 and keratinization marker keratin-10, beyond the effect of calcipotriol monotherapy. However, the combination had a profound effect on, virtually, all T-cell subsets, beyond the effect of the monotherapies. It is concluded that the action spectra of calcipotriol and betamethasone on the psoriatic plaque are different and that the combination has effects on T-cell subsets, beyond the addition of the effects of monotherapies.
Authors:
W H P M Vissers; M Berends; L Muys; P E J van Erp; E M G J de Jong; P C M van de Kerkhof
Related Documents :
8534124 - Functional defect in cells involved in langerhans cell histiocytosis.
22457794 - Muc1 contributes to bpde-induced human bronchial epithelial cell transformation through...
6309654 - T-cell subsets and langerhans cells in wart lesions.
6801234 - An ultrastructural and immunohistochemical study on mandibular lesion of letterer-siwe ...
22777914 - P53 is required for the developmental restriction in müller glial proliferation in mou...
21454804 - Cigarette smoke targets glutaredoxin 1, increasing s-glutathionylation and epithelial c...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Experimental dermatology     Volume:  13     ISSN:  0906-6705     ISO Abbreviation:  Exp. Dermatol.     Publication Date:  2004 Feb 
Date Detail:
Created Date:  2004-03-10     Completed Date:  2004-04-09     Revised Date:  2010-04-12    
Medline Journal Info:
Nlm Unique ID:  9301549     Medline TA:  Exp Dermatol     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  106-12     Citation Subset:  IM    
Affiliation:
Department of Dermatology, University Medical Centre St Radboud, Nijmegen, The Netherlands. w.vissers@derma.umcn.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Inflammatory Agents / administration & dosage,  therapeutic use
Antigens, CD / analysis
Betamethasone / administration & dosage,  therapeutic use*
Calcitriol / administration & dosage,  analogs & derivatives*,  therapeutic use*
Cell Division / drug effects
Dermis / drug effects,  immunology
Drug Therapy, Combination
Epidermis / drug effects,  immunology
Humans
Keratins / metabolism
Ointments
Psoriasis / drug therapy*
Skin / drug effects,  pathology*
T-Lymphocyte Subsets / drug effects,  immunology*
T-Lymphocytes / drug effects,  immunology
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Antigens, CD; 0/Ointments; 112965-21-6/calcipotriene; 32222-06-3/Calcitriol; 378-44-9/Betamethasone; 68238-35-7/Keratins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparative expression of vascular endothelial growth factor family members, VEGF-B, -C and -D, by n...
Next Document:  Tumor necrosis factor-alpha gene expression and release in cultured human dermal microvascular endot...